Staff Profile

Prof Philip Hawkins

Photo

Personal Profile

Name: Philip Hawkins Email: p.hawkins@ucl.ac.uk
Title: Prof Tel:
Department: Inflammation Fax:
Position: Professor of Medicine Address: , , ,
Research Domain: Web Page:  

Profile

Research Description


Research Activities

Education Description

UCL Collaborators

External Collaborators

Publications

    2012

    • Wechalekar AD, Hawkins PN (2012). AL amyloidosis: new drugs and tests, but old challenges.. Oncology (Williston Park), 26(2), 161 - 164.
    • Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.. Blood, 119(19), 4387 - 4390. doi:10.1182/blood-2011-10-388462
    • Pinney JH, Hawkins PN (2012). Amyloidosis.. Ann Clin Biochem, 49(Pt 3), 229 - 241. doi:10.1258/acb.2011.011225

    2011

    • Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, Ferreira A, Lheritier K, Patel N, Preiss R, Hawkins PN, Canakinumab in CAPS Study Group (2011). Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.. Arthritis Res Ther, 13(6), R202 - . doi:10.1186/ar3535
    • Campbell AE, Price AN, Ellmerich S, Simons P, Al-Shawi R, Hawkins PN, Ordidge RJ, Pepys MB, Moon JC, Lythgoe MF (2011). Equilibrium contrast CMR for the detection of amyloidosis in mice. doi:10.1186/1532-429X-13-S1-O60
    • Venner CP, Gillmore JD, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney J, Whelan C, Lachmann H, Hawkins PN, Wechalekar A (2011). Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (> 75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival.
    • Wechalekar A, Schonland SO, Kastritis E, Hawkins PN, Dimopoulos MA, Russo P, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Gillmore JD, Merlini G, Palladini G (2011). European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease.
    • Venner CP, Gillmore JD, Lane T, Foard D, Rannigan L, Gibbs SDJ, Pinney J, Whelan C, Lachmann H, Hawkins PN, Wechalekar A (2011). Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival.
    • Lane T, Rannigan L, Foard D, Wechalekar A, Gibbs S, Pinney J, Venner CP, Banypersad S, Lachmann H, Hawkins PN, Gillmore JD (2011). ALchemy - A Large Prospective 'Real World' Study of Chemotherapy in AL Amyloidosis.
    • Lachmann HJ, Quartier P, So A, Hawkins PN (2011). The emerging role of interleukin-1β in autoinflammatory diseases.. Arthritis Rheum, 63(2), 314 - 324. doi:10.1002/art.30105
    • Sattianayagam PT, Gibbs SD, Rowczenio D, Pinney JH, Wechalekar AD, Gilbertson JA, Hawkins PN, Lachmann HJ, Gillmore JD (2011). Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation.. J Intern Med, , - . doi:10.1111/j.1365-2796.2011.02470.x
    • Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, Gilbertson JA, Hunt T, Gibbs SD, Sattianayagam PT, Pinney JH, Hawkins PN, Gillmore JD (2011). Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.. Am J Pathol, 179(4), 1978 - 1987. doi:10.1016/j.ajpath.2011.06.024
    • Pinney JH, Lachmann HJ, Gillmore JD, Wechalekar A, Gibbs SDJ, Sattianayagam P, Banypersad SM, Dungu J, Wassef N, McCarthy CA, Hawkins PN, Whelan CJ (2011). SENILE SYSTEMIC AMYLOIDOSIS: A COMMON CAUSE OF HEART FAILURE IN THE ELDERLY?. doi:10.1136/heartjnl-2011-300198.103
    • Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN (2011). Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.. Haematologica, 96(7), 1079 - 1080. doi:10.3324/haematol.2011.040493
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SD, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2011). Outcome in renal Al amyloidosis after chemotherapy.. J Clin Oncol, 29(6), 674 - 681. doi:10.1200/JCO.2010.30.5235
    • Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, Hoyer J, Gattorno M, Gul A, Smith J, Leslie KS, Jiménez S, Morell-Dubois S, Davis N, Patel N, Widmer A, Preiss R, Lachmann HJ (2011). Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.. Ann Rheum Dis, 70(12), 2095 - 2102. doi:10.1136/ard.2011.152728

    2010

    • Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010). Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468(7320), 93 - 97. doi:10.1038/nature09494
    • Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2010). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 9(10), 2443 - 2443. doi:10.1111/j.1600-6143.2009.02790.x
    • Wechalekar AD, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Gillmore JD, Gibbs SDJ, Palladini G (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis.
    • Palladini G, Dispenzien A, Gertz MAA, Wechalekar A, Hawkins PN, Schonland SO, Hegenbart U, Comenzo RL, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2010). Validation of the Criteria of Response to Treatment In AL Amyloidosis.
    • Palladini G, Dispenzieri A, Gertz MAA, Wechalekar A, Hawkins PN, Schonland SO, Hegenbart U, Comenzo RL, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2010). Validation of the Criteria of Response to Treatment In AL Amyloidosis.
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases.
    • Wechalekar AD, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Gillmore JD, Gibbs SDJ, Palladini G (2010). A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis.
    • Sattianayagam PT, Gibbs SDJ, Pinney JH, Wechalekar AD, Lachmann HJ, Whelan CJ, Gilbertson JA, Hawkins PN, Gillmore JD (2010). Solid Organ Transplantation in AL Amyloidosis. AM J TRANSPLANT, 10(9), 2124 - 2131. doi:10.1111/j.1600-6143.2010.03227.x
    • Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN (2010). Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.. Blood, 115(21), 4313 - . doi:10.1182/blood-2010-01-261750
    • Simons P, Al-Shawi R, Ellmerich S, Slamova I, Bodin K, Minogue S, Pepys MB, Hawkins PN (2010). Controllable expression of SAA in transgenic mice: a refined model of systemic amyloidosis.
    • Hutt DF, Lane T, Gillmore JD, Lachmann HJ, Gibbs SDJ, Sattianayagam PT, Gopaul D, Quigley AM, Hawkins PN, Wechalekar AD (2010). Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis.
    • Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D, Sattianayagam PT, Gibbs SDJ, Orlandi E, Wassef NL, Bradwell AR, Hawkins PN, Gillmore JD (2010). Clinical outcome of systemic AL amyloidosis affecting the kidneys.
    • Sattianayagam PT, Hahn A, Gibbs SDJ, Whelan CJ, Rowczenio DM, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Gilbertson JA, Hunt T, Gillmore JD (2010). Phenotype and natural history of transthyretin alanine 60 ( T60A) amyloidosis.
    • Sattianayagam PT, Rowczenio DM, Gibbs SDJ, Trojer H, Russell TL, Pinney JH, Lachmann HJ, Wechalekar AD, Hawkins PN, Pepys MB, Gilbertson JA, Hunt T, Gillmore JD (2010). Natural history of hereditary lysozyme amyloidosis.
    • Lachmann HJ, Gillmore JD, Wechalekar AD, Sattianayagam PT, Gibbs SDJ, Pinney JH, Goodman HJB, Offer M, Gallimore JR, Gilbertson JA, Hunt T, Gopaul D, Hutt DF, Hawkins PN (2010). Survival on dialysis and outcome after renal transplantation in AA amyloidosis.
    • Dember LM, Gillmore JD, Lewis WD, Pasquali S, Schoenland SO, Semigran MJ, Hawkins PN (2010). Solid organ transplantation for non-TTR amyloidoses: consensus opinion.
    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Lachmann HJ, Lane T, Goodman HJB, Offer M, Whelan CJ, Rowczenio DM, Hutt DF, Gilbertson JA, Hawkins PN, Wechalekar AD (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study.
    • Wechalekar AD, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Perlini S, Whelan CJ, Hawkins PN, Palladini G (2010). N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis.
    • Gillmore JD, Cocks K, Gibbs SDJ, Sattianayagam P, Lane T, Lachmann HJ, Schey S, Cavenagh J, Oakervee H, Morgan G, Bourne S, Skinner E, Bell S, Booth G, Foard DM, Mehta A, Hawkins PN, Wechalekar AD (2010). UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants.
    • Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2010). Localised amyloid at injection sites derived from porcine and human insulin.
    • Rowczenio DM, Lachmann HJ, Gibbs SDJ, Gilbertson JA, Hunt T, Russell TL, Sattianayagam PT, Trojer H, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2010). Experience of ATTR in a single centre: findings among 220 patients.
    • Lane T, Foard DM, Wechalekar AD, Gibbs SDJ, Lachmann HJ, Sattianayagam PT, Pinney JH, Rannigan LG, Gillmore JD, Hawkins PN (2010). ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK.
    • Sattianayagam PT, Gibbs SDJ, Wechalekar AD, Lachmann HJ, Whelan CJ, Pinney JH, Hawkins PN, Gillmore JD (2010). Solid organ transplantation in AL amyloidosis.
    • Palladini G, Hawkins PN, Foli A, Lachmann HJ, Perlini S, Gillmore J, Merlini G, Wechalekar AD (2010). N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure.
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities.
    • Whelan CJ, Pawarova B, De Cruz M, Lachmann HJ, Sattianayagam PT, Gibbs SDJ, Pinney JH, Gillmore JD, Wassef N, Hawkins PN, Wechalekar AD (2010). Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis.
    • Gibbs SDJ, Sattianayagam PT, Whelan CJ, De Cruz M, Abreu JM, Pinney JH, Pawarova B, Wassef NL, Lane T, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment.
    • Gibbs SDJ, Pinney JH, Sattianayagam PT, Wechalekar AD, Lane T, Rowczenio DM, Offer M, Gilbertson JA, Hunt T, Hawkins PN, Gillmore JD, Lachmann HJ (2010). Light chain deposition disease (LCDD): a case series of 24 patients.
    • Wechalekar AD, Harding S, Lachmann HJ, Gillmore JD, Wassef NL, Thomas M, Gibbs SDJ, Sattianayagam P, Whelan CJ, Bradwell AR, Hawkins PN (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis.
    • Hunt T, Gilbertson JA, Lachmann HJ, Gillmore JD, Gibbs SDJ, Sattianayagam PT, Whelan CJ, Hawkins PN, Wechalekar AD (2010). Unraveling the clonal B cell disease underlying localised AL amyloidosis.
    • Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2010). Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.. J Clin Oncol, 28(6), 1031 - 1037. doi:10.1200/JCO.2009.23.8220
    • Gibbs SD, Hawkins PN (2010). Biochemical basis of the amyloid diseases.. Br J Hosp Med (Lond), 71(2), 70 - 75.
    • Hawkins PN (2010). Systemic amyloidosis: getting to the heart of the matter. BRIT J HOSP MED, 71(2), 66 - 67.
    • Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB (2010). Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.. Br J Haematol, 148(5), 760 - 767. doi:10.1111/j.1365-2141.2009.08036.x
    • Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN (2010). Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases.

    2009

    • Gibbs SDJ, Gillmore JD, Sattianayagam PT, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.
    • Sattianayagam PT, Gibbs SD, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD (2009). Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. American Journal of Transplantation, 10, 2443 - .
    • Gibbs SDJ, Sattianayagam PT, Gillmore JD, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD (2009). Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.
    • Wechalekar AD, Wassef NL, Gibbs SDJ, Gillmore J, Dike F, Lachmann H, Sattianayagam P, Bradwell A, Hawkins PN (2009). A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP..
    • Gillmore J, Cocks K, Gibbs SDJ, Sattianayagam PT, Lane T, Lachmann H, Schey S, Cavenagh JD, Oakervee H, Morgan GJ, Mehta AB, Bourne S, Skinner E, Booth G, Hawkins PN, Wechalekar AD (2009). Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial.
    • Sattianayagam PT, Hawkins PN, Gillmore JD (2009). Systemic amyloidosis and the gastrointestinal tract.. Nat Rev Gastroenterol Hepatol, 6(10), 608 - 617. doi:10.1038/nrgastro.2009.147
    • Kuemmerle-Deschner J, Lachmann HJ, Kone-Paut I, Leslie K, Hachulla E, Quartier P, Krammer G, Patel N, Lheritier K, Preiss R, Hawkins PN (2009). One-year results of canakinumab (ACZ885), a fully human anti-IL-1beta monoclonal antibody in patients with cryopyrin-associated periodic fever syndrome (CAPS). SWISS MED WKLY, 139(31-32), 4S - 4S.
    • Wechalekar AD, Wassef N, Lachmann H, Sattianayagam P, Gibbs SDJ, Gillmore J, Hawkins PN (2009). HIGH EARLY MORTALITY AND POOR OUTCOMES FOR PATIENTS WITH AL AMYLOIDOSIS PRESENTING WITH HIGH SERUM FREE LIGHT CHAINS - A NEW RISK STRATIFICATION MODEL.
    • Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB (2009). Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A, 106(18), 7619 - 7623. doi:10.1073/pnas.0902640106
    • Wechalekar A, Hawkins PN, Wassef NJ, Gillmore ND, Lachmann HJ, Morris J, Thomas M, Bradwell AR, Mead G (2009). Monoclonal Protein Detection in AL Amyloidosis Revisited: Analysis of 642 Patients. CLIN LYMPHOMA MYELOM, 9, S49 - S49.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2009). A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response. CLIN LYMPHOMA MYELOM, 9, S51 - S51.
    • Lachmann HJ, Hawkins PN (2009). Developments in the scientific and clinical understanding of autoinflammatory disorders.. Arthritis Research and Therapy, 11(1), 212 - .
    • Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN (2009). Use of canakinumab in the cryopyrin-associated periodic syndrome.. New England Journal of Medicine, 360(23), 2416 - 2425.
    • Wechalekar AD, Offer M, Gillmore JD, Hawkins PN, Lachmann HJ (2009). Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.. Nature Clinical Practice Cardiovascular Medicine, 6(2), 128 - 133.
    • Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009). Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.. Journal of the American Society of Nephrology, 20(2), 444 - 451.
    • Gibbs SDJ, De Cruz M, Sattianayagam PT, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2009). Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment..

    2008

    • Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2008). Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis.
    • Wechalekar A, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Obici L, Hawkins PN, Palladini G (2008). Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.
    • Gibbs SDJ, Sattianayagam PT, Lachmann HJ, Offer M, Gillmore JD, Hawkins PN, Wechalekar A (2008). Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.
    • Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, Churchman SM, McDermott MF, Hawkins PN (2008). Use of Anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16 month follow-up.. Journal of Cutaneous Medicine and Surgery, 12(1), 8 - 16.
    • Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD (2008). AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 112(10), 4009 - 4016.
    • Wechalekar AD, Lachmann HL, Offer M, Hawkins PN, Gillmoe JD (2008). Efficacy of bortezomib in systemic AL amyloidosis with relapse/refractory clonal disease.. Haematologica, 93(2), 295 - 298.
    • Nedjai B, Hitman GA, Yousaf N, Chernajovsky Y, S P, T R, A H, P N A, P D M, M F T, M D (2008). Abnormal tumour necrosis factor receptor 1 cell surface expression and NF-kappa beta activation in tumour necrosis factor receptor-associated periodic syndrome.. Arthritis and Rheumatism, 58(1), 273 - 283.
    • Wechalekar AD, Hawkins PN, Gillmore JD (2008). Perspective in treatment of amyloidosis. British Journal of Haematology, 140(4), 365 - 377.
    • Gregory ME, Carey M, Hawkins PN, Banerjee S, Gillmore JD (2008). Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant trasnthyretin, Phe33 Val.. British Journal of Ophthalmology, 92(1), 34 - 35.
    • Hamour IM, Lachmann HJ, H J P, M B, M M H, P N B, N R (2008). Heart transplantation for homozygous familial transthyretin (TTR)V1221 cardiac amyloidosis.. American Journal of Transplantation, 8(5), 1056 - 1059.

    2007

    • Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007). Natural history and outcome in systemic AA amyloidosis. New England Journal of Medicine, 356(23), 2361 - 2371. doi:10.1056/NEJMoa070265
    • Selvanayagam JB, Hawkins PN, Paul B, S G N, S (2007). Evaluation and management of the cardiac amyloidosis.. Journal of the American College of Cardiology, 50(22), 2101 - 2110.
    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). Clinical profile and treatment outcome in 103 patients with al amyloidosis associated with IGM paraproteinaemia.
    • Hazenberg BPC, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Filipowicz-Sosnowska A, Gul A, Merlini G, Wiland P, Ozdogan H, Gorevic PD, Ben Maiz H, Benson MD, Direskeneli H, Kaarela K, Garceau D, Hauck W, van Rijswijk MH, Eprodisate AA Amyloidosis Trial Gr (2007). Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. AMYLOID, 14(2), 133 - 140. doi:10.1080/13506120701260224
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). Abnormal NT-ProBNP in AL amyloidosis patients without cardiac involvement at diagnosis - A predictor of subsequent cardiac involvement.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Hawkins PN (2007). A profile of 44 long term survivors (> 10yrs) with AL amyloidosis.
    • Lachmann HJ, Hawkins PN (2007). Eprodisate in AA amyloidosis - Reply. NEW ENGL J MED, 357(11), 1154 - 1154.
    • Lesnyak Q, Butrimiene I, Hazenberg BPC, Hawkins PN, Livneh A, Nasonov EL, Merlini G, Dember LM, Puechal X, Gorevic PD, Garcia JV, Gomez JM, Hunter JA, Garceau D, Hauck W (2007). Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients: 3-year follow-up results.
    • Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN (2007). NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy.
    • Douglass C, Suvarna K, Reilly MM, Hawkins PN, Hadjivassiliou M (2007). A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.. Journal of Neurology, Neurosurgery and Psychiatry, 78(2), 193 - 195. doi:10.1136/jnnp.2006.093500
    • Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007). Safety and efficacy of risk adapted cyclophosphamide,thalidomide and dexamethasone in systemic AL amyloidosis. Blood, 109(2), 457 - 464. doi:10.1182/blood-2006-07-035352
    • Tennent GA, Brennan SO, Stangou AJ, O Grady J, Hawkins PN, Pepys MB (2007). Human plasma fibrinogen is synthesized in the liver. Blood, 109(5), 1971 - 1974. doi:10.1182/blood-2006-08-040956
    • Lachmann HJ, Hawkins PN (2007). Fitzpatrick's Dermatology in General Medicine. Chapter 109 Amyloidosis and the Skin. In (Ed.), (pp. - ). : .
    • Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB (2007). Disease-associated prion protein is not detectable in human systemic amyloid deposits. J Pathol, 213(4), 376 - 383.
    • Hasserjian RP, Goodman HJB, Lachmann HJ, Muzikansky A, Hawkins PN (2007). Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis. Histopathology, 50(5), 567 - 573.
    • Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Butrimiene I, Livneh A, Lesnyak O, Nasonov ELF-S, A G, A M, G W, P O, H G, P D M, H B B, M D D, H K, K G, D H, W VR, M H (2007). Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis.. Amyloid, 14(4), 325 - .
    • Testro AG, Brennan SO, MacDonnell RA, Hawkins PN, Angus RW (2007). Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein A1 Gly26Arg: outcome of hepatorenal transplantation.. Liver Transplant, 13(7), 1028 - 1031.
    • Dember LM, Hawkins PN, Bouke PC, Hazenberg MD, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puechal X, Lachmann H, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M (2007). Eprodisate for the treatment of AA Amyloidosis. New England Journal of Medicine, 356(23), 2349 - 2360. doi:10.1056/NEJMoa065644

    2006

    • Chan-Tack KM, Ahuja N, Weinman EJ, Wali RK, Uche A, Greisman LA, Drachenberg C, Hawkins PN, Redfield RR (2006). Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. AM J MED SCI, 332(6), 364 - 367.
    • Joshi J, Wechalekar AD, Bourdillon PJ, Joshi RP, Rahemtulla A, Hawkins PN (2006). Images in cardiovascular medicine. Intermittent loss of second heart sound.. Circulation, 114(22), e612 - e613. doi:10.1161/CIRCULATIONAHA.106.638510
    • Gillmore JD, Offer M, Lachmann HJ, Goodman HJ, Tennent GA, Gallimore JR, Pepys MB, Hawkins PN (2006). A pilot study of the tolerability, safety and efficacy of CPHPC in patients with systemic amyloidosis.
    • Connolly JO, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN, Woolfson RG (2006). Renal amyloidosis in intravenous drug users.. QJM, 99(11), 737 - 742. doi:10.1093/qjmed/hcl092
    • Hawkins PN, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Gillmore JD (2006). Safety and efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis.
    • Bybee A, Lachmann HJ, Rowczenio DM, Russell T, Goodman HJB, Hawkins PN (2006). Genes associated with inherited periodic fever syndromes (IPFS) in patients with AA amyloidosis of undetermined aetiology.
    • Offer M, Wechalekar AD, Gillmore JD, Lachmann HJ, Hawkins PN (2006). Natural history and outcome of amyloidosis in the elderly.
    • Rowczenio DM, Lachmann HJ, Gillmore JD, Wechalekar AD, Gilbertson JA, Goodman HJB, Hawkins PN, Bybee A (2006). Screening for patients with hereditary systemic amyloidosis.
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Offer M, Joshi JJ, Hawkins PN (2006). NT-ProBNP in AL amyloidosis: changes after chemotherapy and association with survival.
    • Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O'Grady J, Heaton ND, Pepys MB, Hawkins PN (2006). Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant, 6(10), 2342 - 2347. doi:10.1111/j.1600-6143.2006.01507.x
    • Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Hawkins PN, Roberts PF, Grattan CE (2006). The phenotype of patients with cryopyrin-associated periodic syndrome and response to treatment with anti-interleukin 1 (anakinira).
    • Lachmann HJ, Jung T, Bobadilla M, Felix SD, Woessner R, Leslie KS, Offer M, Gratten CE, Hawkins PN, Wright TM (2006). Treatment of muckle wells syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885) - Initial results from a proof of concept study.
    • Hazenberg BP, Bijzet J, Limburg PC, Skinner M, Hawkins PN, Garceau D, Hauck W (2006). Diagnostic performance of amyloid a protein quantification in fat tissue of patients with clinical AA amyloidosis.
    • Lachmann HJ, Sengul B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soyturk M, Akar S, Tunca M, Hawkins PN (2006). Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.. Rheumatology, 45(6), 746 - 750. doi:10.1093/rheumatology/kei279
    • Lachmann HJ, Goodman HJ, Andrews PA, Gallagher H, Marsh J, Breuer S, Rowczenio DM, Bybee A, Hawkins PN (2006). AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases.. Arthritis Rheum, 54(6), 2010 - 2014. doi:10.1002/art.21901
    • Church LD, Churchman SM, Hawkins PN, McDermott MF (2006). Hereditary auto-inflammatory disorders and biologics. SPRINGER SEMIN IMMUN, 27(4), 494 - 508. doi:10.1007/s00281-006-0015-6
    • Goodman HJB, Hawkins PN (2006). Amyloidosis and primary biliary cirrhosis, Rodriguez-Luna et al.. DIGEST DIS SCI, 51(6), 1133 - 1133. doi:10.1007/s10620-006-8020-0
    • Gillmore JD, Hawkins PN (2006). Drug Insight: emerging therapies for amyloidosis.. Nat Clin Pract Nephrol, 2(5), 263 - 270. doi:10.1038/ncpneph0169
    • Hazenberg BPC, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, Hawkins PN, Jager PL (2006). Diagnostic performance of I-123-labeled serum amyloid P component scintigraphy in patients with amyloidosis. AM J MED, 119(4), - . doi:10.1016/j.amjmed.2005.08.043
    • Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN (2006). Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 107(3), 1227 - 1229. doi:10.1182/blood-2005-08-3253
    • Dziadzio M, Anastassiades CP, Hawkins PN, Potter M, Gabrielli A, Brough GM, Black CM, Denton CP (2006). From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. CLIN RHEUMATOL, 25(1), 3 - 15. doi:10.1007/s10067-004-1076-3
    • Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN (2006). Outcome of autologous transplantation for AL amyloidosis in the UK. British Journal of Haematology, 134(4), 417 - 425.
    • Lachmann HJ, Hawkins PN (2006). Amyloidosis and the Lung. Chronic Respiratory Disease, 3, 203 - 214.
    • Lachmann HJ, Hawkins PN (2006). Systemic Amyloidosis. Current Opinion in Pharmacology, 6(2), 214 - 220.
    • Connolly J, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN, Woolfson RG (2006). Renal amyloidosis in injection drug users. Q J Med 2006; (In press). QJM, 99(11), 737 - 742.
    • Gillmore JD, Hawkins PN (2006). Emerging drug therapies for amyloidosis. Nature Clinical Practice Nephrology, 2(5), 263 - 270.
    • Perz JB, Rahemtulla A, Giles C, Szydlo RM, Davis J, Gopaul D, Gillmore J, Mathias CJ, Hawkins PN, Apperley JF (2006). Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplantation, 37(10), 937 - 943.
    • Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP (2006). Targeting C-reactive protein for the treatment of cardiovascular disease. Nature, 440(7088), 1217 - 1221. doi:10.1038/nature04672
    • Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin B, i K, H J, Brewer C, Zalewski C, Wiggs E, Hill S, Turner M, L K, B I, Aksentijevich I, Pucino F, Penzak S, R H, M H, Stein L, Adeams B, S M, T L, Fuhlbrigge R, C S, B J, J N, O'Neil K, Vehe R, K B, L O, Gardner G, Hannan W, P W, R W, Horn W, Cole J, L P, S M, Hawkins P, N P, T H, Snyder C, Wesley R, A H, S C, Holland S, M B, J A, Kastner D, L (2006). Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. New England Journal of Medicine, 355(6), 581 - 592. doi:10.1056/NEJMoa055137
    • Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN (2006). Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol, 142(12), 1591 - 1597.

    2005

    • Offer M, Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Bradwell AR, Hawkins PN (2005). Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay..
    • Dubrey SW, Recica H, Grocott-Mason R, Hawkins PN (2005). Panda eyes and heart failure.. British Journal of Hospital Medicine, 66(12), 701 - .
    • Wechalekar AD, Lachmann HJ, Gillmore JD, Goodman HJB, Offer M, Hawkins PN (2005). The role of renal transplantation in systemic AL amyloidosis..
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Clinical profile and treatment outcome in 92 patients with AL amyloidosis associated with IgM paraproteinaemia..
    • Hazenberg BPC, Bijzet J, Butrimiene I, Livneh A, Lesnyak O, Nasonov EL, Hawkins PN, Filipowicz-Sosnowska A, Merlini G, Obici L, Gui A, Wiland R, Ozdogan H, Gorevic PD, Dember LM, Skinner M, Ben Maiz H, Briand R, Garceau D, Hauck W (2005). Impact of fibrillex, an anti-amyloid product, on amyloid A (AA) protein content in abdominal fat tissue biopsies from patients with AA amyloidosis: Results from a pivotal international trial.
    • Zambarakji HJ, Charteris DG, Ayliffe W, Luthert PJ, Schon F, Hawkins PN (2005). Vitreous amyloidosis in alanine 71 transthyretin mutation. BR J OPHTHALMOL, 89(6), 773 - 774.
    • Goodman HJ, Wechalekar AD, Hawkins PN (2005). Amyloidosis, not myeloma.. British Journal of Haematology, 129(1), 158 - 159.
    • Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005). Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 79(4), 319 - 328.
    • Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ (2005). Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation, 111(2), 186 - 193.
    • Wall JS, Kennel SJ, Paulus MJ, Gleason S, Gregor J, Baba J, Schell M, Richey T, O'Nuallain B, Donnell R, Hawkins PN, Weiss DT, Solomon A (2005). Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis.. Amyloid, 12(3), 149 - 156.
    • Stangou AJ, Heaton ND, Hawkins PN (2005). Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. New England Journal of Medicine, 352, 2356 - .
    • Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D, Sabin CA, Zychlinsky A, de Diego J (2005). Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res, 97(11), e97 - 103.
    • Gyung-Kang H, Bybee A, Soo-Ha I, Park MS, Gilbertson JA, Cheong HI, Choi Y, Hawkins PN (2005). Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aα chain gene.. Kidney International, 68(5), 1994 - 1998.
    • Fisher BA, Lachmann HJ, Rowczenio D, Goodman HJB, Bhalara S, Hawkins PN (2005). Colchicine responsive periodic fever syndrome associated with pyrin I591T.. Annals of the Rheumatic Diseases, 64(9), 1384 - 1385.
    • Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN (2005). Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis..

    2004

    • Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN (2004). Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis..
    • Goodman HJB, Hawkins PN (2004). The role of PBSCT in treatment of AL amyloidosis is far from settled. BLOOD, 104(9), 2991 - 2991.
    • Dubrey SW, Burke MM, Hawkins PN, Banner NR (2004). Cardiac transplantation for amyloid heart disease: the United Kingdom experience.. The Journal of Heart and Lung Transplantation, 23(10), 1142 - 1153.
    • Stangou AJ, Hawkins PN (2004). Liver transplantation in transthyretin-related familial amyloid polyneuropathy.. Current Opinion in Neurology, 17(5), 615 - 620.
    • Hawkins PN, Bybee A, Aganna E, McDermott MF (2004). Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease.. Arthritis and Rheumatism, 50(8), 2708 - 2709.
    • Tunca M, Akar S, Soyturk M, Kirkali G, Resmi H, Akhunlar H, Gonen O, Gallimore JR, Hawkins PN, Tankurt E (2004). The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial.. Clinical and Experimental Rheumatology, 22(4), S37 - S40.
    • Bird J, Cavenagh J, Hawkins P, Lachmann H, Mehta A, Samson D (2004). Guidelines on the diagnosis and management of AL amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 125(6), 681 - 700.
    • Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P (2004). Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade.. Rheumatology, 43(5), 669 - 672.
    • Hu MTM, Gabriel CM, Lachmann HJ, King R, Hawkins PN, Ginsberg L (2004). A faint in the emergency department (due to primary systemic amyloidosis neuropathy).. Practical Neurology, 4(2), 104 - 109. doi:10.1111/j.1474-7766.2004.06-211.x
    • Aganna E, Davidson JE, Cleary G, Sills JA, Bybee A, Drewe E, Hitman GA, Woo P, Hawkins PN, McDermott MF (2004). HETEROGENEITY AMONGST PATIENTS WITH CHRONIC INFANTILE NEUROLOGICAL CUTANEOUS AND ARTICULAR (CINCA) SYNDROME. RHEUMATOLOGY, 43, 21 - 21.
    • Haagsma EB, Hawkins PN, Benson MD, Lachmann HJ, Bybee A, Hazenberg BP (2004). Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families.. Amyloid, 11(1), 44 - 49.
    • Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J (2004). NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.. Immunity, 20(3), 319 - 325.
    • Hawkins PN, Lachmann HJ, Aganna E, McDermott MF (2004). Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.. Arthritis and Rheumatism, 50(2), 607 - 612.
    • Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF (2004). Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun, 5(4), 289 - 293.

    2003

    • Lachmann HJ, McDermott MF, Hawkins PN (2003). AA amyloidosis complicating the hereditary periodic fever syndromes..
    • Hirschfield GM, Hawkins PN (2003). Amyloidosis: new strategies for treatment. The International Journal of Biochemistry and Cell Biology, 35(12), 1608 - 1613.
    • Aganna E, Hawkins PN, Lachmann HJ, Bybee A, Karenko L, Pettersson T, Ranki A, Hitman GA, Woo P, McDermott MF (2003). The spectrum and frequency of MEFV, TNFRSF1A, and NALP3/CIAS1/PYPAF1 mutations in patients with AA amyloidosis associated with systemic inflammation..
    • Elkayam O, Hawkins PN, Lachmann H, Caspi D (2003). Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation: comment on the case report by Elkayam et al - Reply. ARTHRITIS RHEUM, 48(11), 3299 - 3300. doi:10.1002/art.11447
    • Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, Bidwell JL, Castaner JL, Whiteford ML, Janssens-Korpola PL, Manna R, Powell RJ, Woo P, Solis P, Minden K, Frenkel J, Yague J, Mirakian RM, Hitman GA, McDermott MF (2003). Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum., 48(9), 2632 - 2644.
    • Lachmann HJ, Hawkins PN (2003). Diagnosis and management of the inherited periodic fever syndromes. CPD Bulletin Immunology and Allergy, 3, 16 - 19.
    • Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN (2003). Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol, 122(1), 78 - 84. doi:10.1046/j.1365-2141.2003.04433.x
    • Hawkins PN, Lachmann HJ, McDermott MF (2003). Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. New England Journal of Medicine, 348(25), 2583 - 2584. doi:10.1056/NEJM200306193482523
    • Hawkins PN (2003). Hereditary systemic amyloidosis with renal involvement. Journal of Nephrology, 16(3), 443 - 448.
    • Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN (2003). Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology, 42(2), 362 - 366.
    • Lachmann HJ, Hawkins PN (2003). Novel pharmacological strategies in amyloidosis. NEPHRON CLINICAL PRACTICE, 94(4), c85 - c88.
    • Esposito G, Garcia J, Mangione P, Giorgetti S, Corazza A, Viglino P, Chiti F, Andreola A, Dumy P, Booth D, Hawkins PN, Bellotti V (2003). Structural and folding dynamic properties of the T70N variant of human lysozyme. Journal of Biological Chemistry, 278(28), 25910 - 25918.

    2002

    • Aganna E, Zeharia A, Hitman GA, Basel-Vanagaite L, Allotey RA, Booth DR, Hawkins PN, Thacker C, Syndercombe-Court M, M F (2002). An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism, 46(1), 245 - 249.
    • Lachmann HJ, Gilbertson JA, Gillmore JD, Hawkins PN, Pepys MB (2002). Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM, 95(4), 211 - 218.
    • Chelvarajah R, Gnanalingham KK, Hawkins PN, Thomas DGT (2002). Unifocal amyloidosis: a rare cause of spinal cord compression. British Journal of Neurosurgery, 16(1), 58 - 61.
    • Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann H, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffman T, Jakob Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002). Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.. In Bock GR, Goode JA (Ed.), The nature and origin of amyloid fibrils (pp. 73 - 89). : Wiley.
    • Tunca M, Akar S, Hawkins PN, Booth SE, Sengul B, Yavuzsen TU, Oktem S, Soyturk M, Akkoc N, Booth DR (2002). The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. European Journal of Human Genetics, 10(12), 786 - 789.
    • Lachmann HJ, Gillmore JD, Pepys MB, Hawkins PN (2002). Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy..
    • Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Hawkins PN (2002). Changes in the concentration of circulating free immunoglobulin light chains and outcome in systemic AL amyloidosis following chemotherapy..
    • Hawkins PN (2002). Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Current Opinion in Nephrology and Hypertension, 11(6), 649 - 655.
    • Hawkins PN, Lachmann HJ, Pepys MB (2002). Hereditary amyloidosis - Reply. NEW ENGL J MED, 347(15), 1207 - 1207.
    • Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D (2002). Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis and Rheumatism, 46(10), 2571 - 2573.
    • Swift B, Hawkins PN, Richards C, Gregory R (2002). Examination of insulin injection sites: an unexpected finding of localized amyloidosis. DIABETIC MED, 19(10), 881 - 882.
    • Lachmann HJ, Booth DR, Bybee A, Gillmore JD, Hawkins PN (2002). Frequency of hereditary systemic amyloidosis masquerading as immunoglobulin light chain, AL (primary), amyloidosis.. J AM SOC NEPHROL, 13, 39A - 39A.
    • Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN (2002). Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med, 346(23), 1786 - 1791. doi:10.1056/NEJMoa013354
    • Gribbin GM, Gilbertson JA, Hawkins PN (2002). Diagnosis of amyloidosis by histological examination of subcutaneous fat sampled at the time of pacemaker implantation. Heart, 87(6), e7 - .
    • Shah PL, Gillmore JD, Copley SJ, Collins JV, Wells AU, du Bois RM, Hawkins PN, Nicholson AG (2002). The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases, 19(2), 134 - 142.
    • Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN (2002). Detection of monoclonal free light chains by nephelometry in 262 patients with systemic AL amyloidosis.. CLIN CHEM, 48(6), A164 - A165.
    • Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Bradwell AR, Hawkins PN (2002). Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis.. CLIN CHEM, 48(6), A165 - A165.
    • Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 417(6886), 254 - 259. doi:10.1038/417254a
    • Harrison CJ, Mazzullo H, Ross FM, Cheung KL, Gerrard G, Harewood L, Mehta A, Lachmann HJ, Hawkins PN, Orchard KH (2002). Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 117(2), 427 - 435.
    • Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF (2002). Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum., 46(9), 2445 - 2452.

    2001

    • Booth DR, Bellotti V, Mangione P, Booth S, Sunde M, Serpell LC, Robinson CV, Pepys MB, Hawkins PN (2001). Is lysozyme variant Thr70Asn amyloidogenic?.
    • Hawkins PN (2001). Phenotypes and fibril types in systemic amyloidosts.
    • Hawkins PN (2001). 10 years experience with serum amyloid P component scintigraphy.
    • Booth DR, Lachmann HJ, Gillmore JD, Booth SE, Hawkins PN (2001). Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. QJM, 94(10), 527 - 531.
    • Lachmann HJ, Hawkins PN (2001). Amyloidosis:rheumatic disease and amyloid;clinical features and treatment. In Adu D, Emery P, Madaio MP (Ed.), Rheumatology and the Kidney (pp. 322 - 348). : Oxford University Press.
    • Dubrey SW, Burke MM, Khaghani A, Hawkins PN, Yacoub MH, Banner NR (2001). Long term results of heart transplantation in patients with amyloid heart disease. Heart, 85(2), 202 - 207.
    • Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001). Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet, 358(9275), 24 - 29. doi:10.1016/S0140-6736(00)05252-1
    • Lachmann HJ, Hawkins PN (2001). Amyloidosis:Pathogenesis and Diagnosis. In Adu D, Emery P, Madaio MP (Ed.), Rheumatology and the Kidney (pp. 305 - 321). : Oxford University Press.
    • Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O'Grady J, Rela M, Heaton ND, Wall CA, Keogh JA, Hawkins PN (2001). Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation, 71(7), 986 - 992.

    2000

    • McDermott MF, Aganna E, Hitman GA, Ogunkolade BW, Booth DR, Hawkins PN (2000). An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q. Arthritis and Rheumatism, 43(9), 2034 - 2040.
    • Booth DR, Pepys MB, Hawkins PN (2000). A novel variant of human lysozyme (T70N) is common in the normal population. Hum Mutat, 16(2), 180 - .
    • Gillmore JD, Madhoo S, Pepys MB, Hawkins PN (2000). Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy. Nucl Med Commun, 21(8), 735 - 740.
    • Lachmann HJ, Booth DR, Bybee A, Hawkins PN (2000). Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese-Taiwanese family. Human Mutation, 16(2), 180 - .
    • Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M (2000). Bleeding symptoms and coagulation abnormalities in 337 patients with AL- amyloidosis. British Journal of Haematology, 110(2), 454 - 460.
    • Gillmore JD, Booth DR, Rela M, Heaton ND, Rahman V, Stangou AJ, Pepys MB, Hawkins PN (2000). Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. QJM, 93(5), 269 - 275.
    • Booth DR, Gillmore JD, Lachmann HJ, Booth SE, Bybee A, Soytürk M, Akar S, Pepys MB, Tunca M, Hawkins PN (2000). The genetic basis of autosomal dominant familial Mediterranean fever. QJM, 93(4), 217 - 221.
    • Booth DR, Stangou A, Williams RS, Gillmore JD, Tennent GA, Hawkins PN (2000). Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy. Human Mutation, 16(5), 447 - .
    • Elliott PM, Mahon NG, Matsumura Y, Hawkins PN, Gillmore JD, McKenna WJ (2000). Tissue Doppler features of cardiac amyloidosis. Clinical Cardiology, 23(9), 701 - .

    1999

    • Tan SY, Baillod R, Brown E, Farrington K, Soper C, Percy M, Clutterbuck E, Madhoo S, Pepys MB, Hawkins PN (1999). Clinical, radiological and serum amyloid P component scintigraphic features of β2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant, 14(6), 1467 - 1471.
    • Gillmore JD, Booth DR, Pepys MB, Hawkins PN (1999). Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart, 82(3), e2 - .
    • Brett M, Persey MR, Reilly MM, Revesz T, Booth DR, Booth SE, Hawkins PN, Pepys MB, Morgan-Hughes JA (1999). Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis. Brain, 122(2), 183 - 190.
    • Gillmore JD, Booth DR, Madhoo S, Pepys MB, Hawkins PN (1999). Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant, 14(11), 2639 - 2644.
    • Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999). Acute phase response and evolution of familial Mediterranean fever. Lancet, 353(9162), 1415 - .
    • Tennent GA, Cafferty KD, Pepys MB, Hawkins PN (1999). Congo red overlay immunohistochemistry aids classification of amyloid deposits.. In Kyle RA, Gertz MA (Ed.), Amyloid and amyloidosis 1998: the proceedings of the VIIIth International Symposium on Amyloidosis, August 7-11, 1998, Rochester, Minnesota, USA (pp. 160 - 162). : Parthenon Publishing, Pearl River, New York..

    1998

    • Lovat LB, Obrien AAJ, Armstrong SF, Madhoo S, Bulpitt CJ, Rossor MN, Pepys MB, Hawkins PN (1998). Scintigraphy with I-123-serum amyloid P component in Alzheimer disease. Alzheimer Disease and Associated Disorders, 12, 208 - 210.
    • Stangou AJ, Heaton ND, Rela M, Pepys MB, Hawkins PN, Williams R (1998). Domino hepatic transplantation using: The liver from a patient with familial amyloid polyneuropathy. TRANSPLANTATION, 65(11), 1496 - 1498.
    • Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O'Grady J, Pepys MB, Williams R (1998). Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy - Implications for amyloid fibrillogenesis. TRANSPLANTATION, 66(2), 229 - 233.
    • Stangou AJ, Heaton ND, Rela M, Pepys MB, Hawkins PN, Williams R (1998). Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. Transplantation, 65(11), 1496 - 1498.
    • Persey MR, Booth DR, Booth SE, van Zyl-Smit R, Adams BK, Fattaar AB, Tennent GA, Hawkins PN, Pepys MB (1998). Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I.. Kidney International, 53, 276 - 281.
    • Booth DR, Gillmore JD, Persey MR, Booth SE, Cafferty KD, Tennent GA, Madhoo S, Cochrane SW, Whitehead TC, Pasvol G, Hawkins PN (1998). Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family.. Human Mutation, 12, 135 - .
    • Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, O'Grady J, Pepys MB, Williams R (1998). Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation, 66(2), 229 - 233.

    1997

    • Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, OGrady J, Pepys MB, Williams R (1997). Progressive restrictive cardiomyopathy following orthotopic liver transplantation for familial amyloid polyneuropathy.. HEPATOLOGY, 26(4), 869 - 869.
    • Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.. Nature Medicine, 3, 855 - 859.

    1996

    • Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN, Bruguera M, Caballería J, Solé M, Campistol JM, Pepys MB (1996). Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.. Journal of Clinical Investigation, 97(12), 2714 - 2721.

    1995

    • Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL, Thomson N, Soutar AK, Hawkins PN, Pepys MB (1995). A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. Quarterly Journal of Medicine, 88(10), 695 - 702.

    1994

    • Tan SY, Murdoch IE, Sullivan TJ, Wright JE, Truong O, Hsuan JJ, Hawkins PN, Pepys MB (1994). Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain. Clinical Science (London), 87(5), 487 - 491.
    • PEPYS MB, RADEMACHER TW, AMATAYAKULCHANTLER S, WILLIAMS P, NOBLE GE, HUTCHINSON WL, HAWKINS PN, NELSON SR, GALLIMORE JR, HERBERT J, HUTTON T, DWEK RA (1994). HUMAN SERUM AMYLOID-P COMPONENT IS AN INVARIANT CONSTITUENT OF AMYLOID DEPOSITS AND HAS A UNIQUELY HOMOGENEOUS GLYCOSTRUCTURE. P NATL ACAD SCI USA, 91(12), 5602 - 5606.
    • Vigushin DM, Hawkins PN, Hsuan JJ, Totty NF, Pepys MB (1994). AL kappa amyloid in a solitary extradural lymphoma. Journal of Neurology, Neurosurgery and Psychiatry, 57(6), 751 - 754.

    • Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dillon AP, Taylor GW, Bradwell AR, Petrie A, Gilmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (). Antibodies to human amyloid P component eliminate visceral amyloid deposits. Nature, 468(7320), 93 - 97. doi:10.1038/nature09494
    • Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene L, A L, O P, X L, H O, L B, R G, D H, W AS, M FTEFAATG (). Eprodisate for the Treatment of AA Amyloidosis. New England Journal of Medicine, , - .
    • Tennent GA, Gillmore JD, Lachmann HJ, Rowczenio D, Weldon M, Bybee AJ, Gilbertson J, Hamilton DV, Ball RY, Packman L, Hawkins PN, Pepys MB (). Heterozygous gelsolin Asp187Asn causes hereditary renal amyloidosis. , , - .
    • Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Peden AH, McCardle LM, Ironside JW, Pepys MB (). Comment on "Prion-Induced Amyloid Heart Disease with High Blood Infectivity in Transgenic Mice".. Science, , - .